‪Bruce Riser, AB,MA,PhD
‬Medical Products Division‪
‬Baxter Healthcare Corporation‪
Chicago, Il
USA
Tel: ‬847-473-6344‪
Cell phone: ‬269-830-1631‪
bruce_riser@baxter.com

Present Position

‬Director- Research, Development & SCIENTIFIC support‪, ‬
Medical Products Division, Baxter Healthcare Corporation,Chicago, IL, USA
‪‬Adjunct Professor of Physiology and Biophysics
Laboratory director
Rosalind Franklin Univ. of Medicine and Science, North Chicago, IL.
Adjunct Professor of Medicine,
Dept. of Medicine,
Chicago Medical School, North Chicago, IL.

Awards

• Juvenile Diabetes Found. International Award 2001-2006
• American Diabetes Association Award 2000-2004
• Juvenile Diabetes Found. International Award 1998-2007
• National Kidney Found. Award 1997-1998
• National Kidney Found. Award 1994-1995
• Henry Ford Hospital Found. Award 1993-1998
• Juvenile Diabetes Found. International Award 1992-1994
• Young Invest. Award, Forefronts in Nephrology Symposium,
  International Soc. of Nephrology, Kloster Banz, Germany1991

Scientific Review

• Journal of Cell Signaling and Communication- Associate editor
• Lancet
• Current Stem Cell Therapy
• Clinical Chemistry
• Am. Journal Pathology
• Journal Am. Society of Nephrology
• Kidney International
• Hypertension
• Peritoneal Dialysis International
• Life Sciences
• Clinical Chemistry
• Cancer Cell International
• Nephrology Dialysis and Transplantation
• Current Stem Cell Review and Therapy
• National Kidney Foundation (Grant review)
• Diabetes Fonds Nederland (Grant review)
• Health Research Board of Ireland (Grant review)

Goals and primary research interests

• Scientific goals are to indentify novel pathways to disease, then to utilize that knowledge to discover, develop and deliver novel therapy to prevent and/or treat disease, thus extending suffering-free, disease-free life.
• Long-term emphasis has been on the factors leading to progressive renal disease, particularly that associated with diabetes, and the prevention of kidney failure. Also of focus are the prevention and/or treatment of complications that arise as the result of kidney disease, including vascular calcification and cardiovascular disease and stroke.
• Work in the former area has focused on the role of growth factors, cytokines, and matricellular proteins, e.g. the CCN family of genes, as agonists and antagonists of fibrosis / sclerosis and tissue regeneration. At a cell- molecular level focus has been on extracellular matrix biology, remodeling and repair in response to injury. . In the latter area, focus has been on the creation of better dialysis and/or drug-based treatments associated with dialysis.

Recent publications

• Riser, BL, M DeNichilo, P Cortes, C Baker, J Yee, RG Narins:
  Regulation of connective tissue growth factor (CTGF) activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis.
  J Amer Soc Nephrol 11:25-38, 2000.
• Cortes, P, J Yee, BL Riser, CJ Guerin, A Rodriguez-Barbero, C Rucker, M. Mendez:
  F-actin fiber distribution in glomerular cells: structural and functional implications.
  Kidney Int 58:2452-2461, 2000.
• Riser, BL, J Varani, P Cortes, J Yee, M Dame, A K Sharba:
  Cyclic stretch of mesangial cells upregulates intercellular adhesion molecule-1 (ICAM-1) and leukocyte adherence: a possible new mechanism for glomerulosclerosis
  Am J Pathology 158:11-17, 2001.
• Riser, Bl, P Cortes:
  Connective tissue growth factor and its regulation: a new element in diabetic glomerulosclerosis.
  Renal Failure 23:459-470, 2001.
• Ader S, SW Kang, S Field, DR Cha, L Barbra, L Stricker, G Stricker, B Riser, J LaPage, CC Nast:
  Glomerular mRNAs in human type 1 diabetes: Biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy.
  Kidney Int 60:2330-2336, 2001.
• Szamosfalvi, B, P Cortes, R Alviani, K Asano, BL Riser, G. Zasuwa, J Yee:
  Putitive subunits of the rat mesangial cell KAPT: a type 2B sulfonylurea receptor (SUR2B) and an inwardly-rectifying K channel
  Kidney Int, 61, 2002.
• Adler S., SW Kang, S. Field, DR Cha, L Barbra, L Striker, G Striker, BL Riser, J LaPage, CC Nast:
  Can glomerular mRNAs in human Type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria? A case report.
  Am J Kid Dis 40:184-188, 2002.
• Brigstock, DR, R Goldschmeding, K-i Katsube, S C-T Lam, L F Lau, K Lyons, C Naus, B Perbal, B Riser, M Takigawa, H Yeger:
  Proposal for a unified CCN nomenclature:
  J Clin Path: Mol Path 56: 127-128, 2003
• Riser, BL, P Cortes, M DeNichilo, PV Deshmukh and PS Chahal, A. K. Mohammed, J Yee, D. Kahkonen:
  Urinary CCN2 (CTGF): as a possible predictor of diabetic nephropathy: Preliminary report,
  Kidney Int. 64:451-458, August, 2003.
• Cooker, LA, F Najmabadi, D Peterson and BL Riser:
  TNF-alpha, but not IFN-gamma regulates CCN2 (CTGF), collagen type I and proliferation in mesangial cells: possible roles in the progression of renal fibrosis.
  Am J Renal Physiology, 293: F157-F165, 2007.
• Haydont, V, BL Riser, C Bourgier, J Aigueperse, and MC Vozenin-Brotons:
  Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: a role for CCN2 and low concentration of TGF 1.
  Am. J. Physiol Cell, 294: C1331-41, 2008.
• Riser, BL, F Najmabadi, B Perbal, DR Peterson, JA Rambow, ML Riser, E Sukowski, H Yeger and SC Riser:
  CCN3 (Nov) is A Negative Regulator of CCN2 (CTGF) and a Novel Endogenous Inhibitor of the Fibrotic Pathway in an In Vitro Model of Renal Disease.
  Am. J. Pathology, 174:1725-1734 2009
• F W.K. Tam, BL Riser, K Meeran, J Rambow, CD Pusey and AH. Frankel:
  Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy,
  Cytokine, 47, 1:37-42 2009
• Riser, BL, F Najmabadi, B Perbal, JA Rambow, ML Riser, E Sukowski, H Yeger and SC Riser, DR Peterson:
  CCN3/CCN2 regulation and the fibrosis of diabetic renal disease.
  J Cell Commun Signal, 1:39-50, 2010
• Cozzolino, M, ML Biondi, E Banfi, BL Riser, F Mehmeti, D Cusi and M Gallieni:
  CCN2 (CTGF) gene polymorphism is a novel prognostic risk factor for cardiovascular outcomes in hemodialysis patients.
  Blood Purif 30:272-276, 2010.
• O'Neill,C, KA Lomashvili, HH Malluche, MC Faugere and BL Riser,
  Treatment with pyrophosphate inhibits uremic vascular calcification.
  Kidney Int, advance online publication 1 December 2010.
• Riser, BL, FC Barreto, R Rezg, PW Valaitis, CS Cook, JA White, JH Gass, J Maizel, L Louvet, TB Drueke, CJ Holmes and ZA. Massy:
  Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uremia,
  Nephrology, Dialysis and Transplantation, in press, January, 2011

Recent Books Chapters and Reviews

• Riser, BL, P Cortes, J Yee:
  Modeling the effects of vascular stress in mesangial cells.
  In: Current Opinion Nephrol and Hypertension, Circulation and Hemodynamics. 9: 43-47,
  B Brenner, L Dworkin, MR Hammerman (ed) Lippincott Williams & Wilkins, London, 2000.
• Riser, BL, P Cortes:
  Pressure-induced and metabolic alterations in the glomerulus: Role in cytokine activity and progressive sclerosis.
  In: The Kidney and Hypertension in Diabetes Mellitus. Fifth Edition, 1-12.
  CE Mogensen (ed), Kluwer Academic Publishers, Boston, 2000.
• Riser, BL, S. Karoor, D. Peterson:
  CCN genes and the kidney.
  In CCN proteins: a New Family of Cell Growth and Differentiation Regulators,
  Bernard Perbal and Masaharu Takigawa (ed), Imperial College Press, May, 2005.
• Riser, BL:
  CCN2 (CTGF) in the pathogenesis of diabetic renal disease: A target for therapeutic intervention.
  In: Contemporary Diabetes: The Diabetic Kidney,
  CE Mogensen & P. Cortes (eds), Humana Academic Publishers, Totowa, NJ, June 2006.
• Riser, BL, F Najmabadi, B Perbal, JA Rambow, ML Riser, E Sukowski, H Yeger and SC Riser, DR Peterson:
  CCN3 (NOV): A Negative Regulator of CCN2 (CTGF) Activity and an Endogenous Inhibitor of Fibrosis.
  In CCN Proteins in Health and Disease,
  A. Perbal, M. Takigawa and B. Perbal (ed) Springer, 2010.